European pharmaceutical companies are being squeezed by President Donald Trump's aggressive trade and drug-pricing policies, and China's biotech boom. The pharma industry is a crucial part of Europe's economy, but its competitiveness is waning due to declining competitiveness. New launches of critical medicines are at risk due to high prices and uncertainty surrounding the U.S. and most-favored-nation pricing policies. Meanwhile, China has emerged as a leader in biotech, becoming a key player in the industry. The U.K. continues to be the most important market for pharma companies due to its high medicine prices. However, most-favorite-nation drug pricing could threaten pharma firms' profit margins. The industry needs to lead in life-saving measures to prevent future loss of investment away from Europe.